Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2026HaematologicaOpen Access

Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

JWJustin M. WattsEMEllen MadarangDADiana Abbott

Discussion

Loading...

Member takes

Overview

This trial evaluates the efficacy of venetoclax and azacitidine in younger acute myeloid leukemia patients, indicating significant benefits compared to intensive chemotherapy.

Key Points

  • The study aims to assess the toxicity and efficacy of venetoclax and azacitidine in younger patients with acute myeloid leukemia, independent of their fitness for intensive chemotherapy.
  • Conducted a trial with younger AML patients (≤60 years) receiving venetoclax and azacitidine.
  • Enrolled subjects with non-favorable risk disease to evaluate treatment outcomes.
  • Patients were encouraged to undergo allogeneic stem cell transplant in first remission.
  • Monitored adverse effects and treatment responses over a median follow-up of 2.9 years.
  • Overall response rate (ORR) was 69%, with 53% achieving complete remission.
  • Significant improvement in ORR and stem cell transplant rates compared to intensive chemotherapy matched controls.
  • Common adverse effects included grade ≥3 neutropenia (42%) and thrombocytopenia (53%).
  • Median progression-free survival and overall survival were not reached, indicating long-term efficacy.

Cite This Study

Watts et al. (2026) studied this question.

synapsesocial.com/papers/69a3d79dec16d51705d2dd6dhttps://doi.org/10.3324/haematol.2025.300374
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world evidence on the use of lower-intensity treatment with venetoclax and azacitidine in newly diagnosed AML in younger patients2026
  2. 2Results from paradigm - a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia2025 · 33 citations
  3. 3Intensive chemotherapy versus venetoclax–hypomethylating agents therapy for acute myeloid leukemia: A large real-world propensity-matched study.2026
  4. 4Venetoclax and azacytidine in childhood primary advanced myelodysplastic syndromes, refractory/relapsed Acute Myeloid Leukemia and therapy-related myeloid diseases2025
  5. 5Reduced intensive chemotherapy combined with venetoclax in adult patients with Acute Myeloid Leukemia: A retrospective single-center analysis2025